Monash University

NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease

Retrieved on: 
Tuesday, April 9, 2024
Disability, Cardiovascular disease, Myocardial infarction, CVD, Risk, Patient, Stroke, NAMS, History, Mortality, Death, FESC, Moyamoya disease, Phase 3, Monash University, MACE, ASCVD, Hypercholesterolemia, Pharmaceutical industry

Driven by strong patient and physician interest globally, NewAmsterdam will extend enrollment to the end of April where we expect to randomize over 9,000 patients.

Key Points: 
  • Driven by strong patient and physician interest globally, NewAmsterdam will extend enrollment to the end of April where we expect to randomize over 9,000 patients.
  • “PREVAIL, our pivotal CVOT, will potentially demonstrate that obicetrapib’s lowering of LDL-C will reduce major adverse cardiac events (“MACE”).
  • The primary objective of the study is to evaluate the effect of obicetrapib compared to placebo on MACE, including cardiovascular death, myocardial infarction, stroke and non-elective coronary revascularization.
  • “Despite widespread availability of statin therapies, CVD-related deaths are on the rise, and many patients are not at their risk-based LDL-C goals.

PanTher Therapeutics Presents Positive First-in-Human Data for PTM-101 in Pancreatic Cancer at AACR Annual Meeting

Retrieved on: 
Monday, April 8, 2024
Oncology, Health, Surgery, Clinical Trials, Pharmaceutical, Biotechnology, Toxicity, Infection, Associate, Patient, Cancer, Doctor of Philosophy, MD, Panther, AACR, Pancreatic cancer, Neoplasm, Clinical trial, Therapy, Paclitaxel, Pancreas, Pancreatitis, Safety, Monash University, Prognosis, Pharmaceutical industry

PTM-101 was placed directly onto the pancreas, overlying the location of the tumor using standard laparoscopic equipment as part of a disease staging assessment.

Key Points: 
  • PTM-101 was placed directly onto the pancreas, overlying the location of the tumor using standard laparoscopic equipment as part of a disease staging assessment.
  • Once in place over the tumor site, PTM-101 locally delivered a sustained dose of the chemotherapeutic agent over four weeks.
  • Approximately three weeks after placement of PTM-101, all participants began standard of care therapy, which included treatment with mFOLFIRINOX.
  • Results of the clinical trial demonstrated that PTM-101 reduced the size of pancreatic tumors in all three patients.

60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris

Retrieved on: 
Tuesday, February 20, 2024
Infection, Bangladesh Technical Education Board, Fungus, Hospital, Candida auris, NIAID, NIH, Marketing, FDA, Food, Tafenoquine, Risk, Malaria, Patient, Monash University, Oxidative stress, Ageing, Research, Fungal infection, Pharmaceutical industry

C. auris, a strain of fungal yeast, is an emerging pathogen that poses risk of serious infection in the bloodstream and elsewhere, especially in hospitalized patients.

Key Points: 
  • C. auris, a strain of fungal yeast, is an emerging pathogen that poses risk of serious infection in the bloodstream and elsewhere, especially in hospitalized patients.
  • The study will be conducted by Monash University in Melbourne, Australia, beginning in the second quarter of 2024.
  • “The rapid transmission of Candida auris in healthcare facilities is a very real threat and the need for a safe, effective treatment option is becoming more urgent every day,” said 60 Degrees Pharmaceuticals Chief Executive Officer and President, Geoff Dow.
  • Like other 8-aminoquinoline antimalarials, tafenoquine is expected to kill fungi by disrupting cellular responses to oxidative stress, differentiating it from other antifungals.

BiVACOR® Receives $13 Million to Support Clinical Trials for the Company’s Total Artificial Heart

Retrieved on: 
Tuesday, February 20, 2024
Health, Medical Devices, Surgery, Health Technology, General Health, Clinical Trials, Cardiology, The Alfred Hospital, USD, Multimedia, University of Queensland, The Texas Heart Institute, University, FDA, Cancer, Hospital, IDE, Artificial heart, Griffith University, Heart failure, MRFF, Fatigue, TAH, Patient, Monash University, Survival, Periodic breathing, EFS, Pharmaceutical industry

BiVACOR® , a clinical-stage medical device company, today announced $13 million (USD) awarded from the Australian Government’s Medical Research Future Fund (MRFF) grant through the Artificial Heart Frontiers Program (AHFP) to support BiVACOR’s Total Artificial Heart program and future product enhancements.

Key Points: 
  • BiVACOR® , a clinical-stage medical device company, today announced $13 million (USD) awarded from the Australian Government’s Medical Research Future Fund (MRFF) grant through the Artificial Heart Frontiers Program (AHFP) to support BiVACOR’s Total Artificial Heart program and future product enhancements.
  • View the full release here: https://www.businesswire.com/news/home/20240220429887/en/
    BiVACOR® Total Artificial Heart (TAH) in Surgeon's Hands (Photo: Business Wire)
    Led by Monash University, the AHFP is comprised of a consortium of research centers in Australia in collaboration with BiVACOR.
  • The award will support clinical work of the BiVACOR Total Artificial Heart (TAH) and begin development for the integration of wireless power sources for the device.
  • “There is a huge gap between available treatment options and the number of patients with severe heart failure.

Korean Government Delegation and KACES Conclude Successful 3rd UNESCO World Conference on Culture and Art Education

Retrieved on: 
Monday, February 19, 2024
Primary, Secondary, Arts, Museums, Education, Entertainment, Music, Other Education, University, UNESCO, Ministry, Sir, Multimedia, Professor, Value, Access, Group Policy, Yonsei University, Multilateralism, Conference, Digital technology, MSCT, School, MCST, Policy, Monash University, Sport, Elected, UN, Hansung University, Speech, Management

The Ministry of Culture, Sports and Tourism (MCST, Minister: Yu In-chon) and Korea Arts & Culture Education Service (KACES, President: Park Eun-sil) participated in the 3rd UNESCO World Conference on Culture and Arts Education, held in Abu Dhabi, United Arab Emirates from February 13th to 15th.

Key Points: 
  • The Ministry of Culture, Sports and Tourism (MCST, Minister: Yu In-chon) and Korea Arts & Culture Education Service (KACES, President: Park Eun-sil) participated in the 3rd UNESCO World Conference on Culture and Arts Education, held in Abu Dhabi, United Arab Emirates from February 13th to 15th.
  • View the full release here: https://www.businesswire.com/news/home/20240219103477/en/
    The 3rd UNESCO World Conference on Culture and Arts Education is held in Abu Dhabi, United Arab Emirates (Photo: KOREA ARTS & CULTURE EDUCATION SERVICE)
    Held for the first time since 2010's Seoul event, the 3rd UNESCO World Conference on Culture and Arts Education aimed to reflect evolving social values and adopt the revised Framework for Culture and Arts Education.
  • During the first session, MCST's Culture and Arts Policy Director, Lee Hae-don, gave a presentation titled "A Fair Opportunity for Access to Culture and Arts Education."
  • A MCST official said, “In this conference, which was aimed at discussing the directivity of global culture and arts education, Korea’s leadership in the field of culture and arts education was demonstrated.”
    View source version on businesswire.com: https://www.businesswire.com/news/home/20240219103477/en/

Titan Machinery Elects New Board Member

Retrieved on: 
Thursday, January 18, 2024
Titan, Region, Chairperson, Employment, Mining, Business, Executive, Caterpillar Inc., Titan Machinery, Acquisition, Monash University, Marketing, Tractor, Caterpillar, Film industry

WEST FARGO, N.D., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Titan Machinery Inc. (NASDAQ:TITN) announced today that it has elected Richard E. Lewis to its Board of Directors.

Key Points: 
  • WEST FARGO, N.D., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Titan Machinery Inc. (NASDAQ:TITN) announced today that it has elected Richard E. Lewis to its Board of Directors.
  • With the election of Mr. Lewis, the Board will consist of nine directors, including seven independent directors.
  • “We are pleased that Richard has accepted the invitation to join our Board of Directors,” said David Meyer, Titan Machinery’s Board Chair and CEO.
  • We believe that Titan Machinery and our Board will benefit from Richard’s valuable and unique business experience.”
    Mr. Lewis currently serves as director and the principal executive of Iron Capital Group, a company founded by Mr. Lewis in 2015.

Incannex Completes Dosing and Therapy in Phase 2 “PsiGAD” Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis Commences

Retrieved on: 
Thursday, January 18, 2024
Data monitoring committee, Patient, Research, Clutch (eggs), DSMB, Anxiety disorder, GAD, Safety, Mental health, Quality of life, Unknown, Monash University, FDA, SBS, Clinical trial, Television, Pharmaceutical industry

MELBOURNE, Australia and NEW YORK, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex’ or the ‘Company’), a pharmaceutical company developing unique medicinal cannabinoid pharmacotherapies and psychedelic medicine therapies is pleased to announce that it has completed dosing and treatment protocols for all 72 participants in the PsiGAD-1 clinical trial, the Company’s Phase 2 study evaluating its own psilocybin treatment program for patients with generalized anxiety disorder (GAD).

Key Points: 
  • Independent documentary covering Monash Clinical Psychedelic Lab and PsiGAD research program to be released by SBS television network following 2 years of filming and production.
  • PsiGAD-1 is a randomised triple-blind active-placebo-controlled Phase 2 trial.
  • “Generalised anxiety disorder is characterised by persistent, debilitating and excessive worry, affects millions of people globally, and has inadequate existing treatment options.
  • An independent Data Safety Monitoring Board (DSMB) was tasked with confidentially reviewing the data for the first 37 out of 72 trial participants.

UiPath Expands Customer Leadership with Appointment of Pradeep Kumar as Senior Vice President of Services and Customer Success

Retrieved on: 
Monday, January 22, 2024
Other Professional Services, Software, Human Resources, Artificial Intelligence, Data Management, Professional Services, Technology, Other Technology, Hewlett Packard Enterprise, Senior, Customer success, Business, AI, HPE, Monash University, Automation

UiPath (NYSE: PATH), a leading enterprise automation software company, today announced Pradeep Kumar is joining the company as Senior Vice President of Services and Customer Success.

Key Points: 
  • UiPath (NYSE: PATH), a leading enterprise automation software company, today announced Pradeep Kumar is joining the company as Senior Vice President of Services and Customer Success.
  • Reporting to Chief Customer Officer Kelly Ducourty, Kumar will lead the company’s strategic initiatives to enable customer success through unparalleled support and execution of digital transformation goals with the UiPath Business Automation Platform.
  • Most recently, Kumar worked as Senior Vice President and General Manager, HPE Services at Hewlett-Packard Enterprise, where he led the HPE services business to assist companies with accelerating digital transformation.
  • Previously, he served as Senior Vice President of Global Shared Delivery at HPE, a worldwide organization responsible for delivering solutions and services to HPE customers.

What will you read on the beach this summer? We asked 6 avid readers

Retrieved on: 
Saturday, December 30, 2023
Napoleon, Associate, Senior lecturer, University of Tasmania, War, Man, Pan Books, Heart, Violence, Tennis, Season, Babel, Death, Closet, Between You and Me, Swinburne University of Technology, Culture, Samuel R. Delany, Communication, Breakfast, Female, Deakin University, A Wild Sheep Chase, Simon & Schuster, DIY, Demon Copperhead, Literature, University, New Wave, History, Travel, Middlemarch, Dashiell, New Yorker, Bachelor, Creative writing, Dhalgren, University of Melbourne, Book, Anglo-French Wars, Department, Ovis, Love contract, Emeritus, Water, Monash University, The Love Contract

That might be a traditional beach read – typically a genre paperback with a propulsive plot – or an opportunity to catch up on the classics you never got around to during the year.

Key Points: 
  • That might be a traditional beach read – typically a genre paperback with a propulsive plot – or an opportunity to catch up on the classics you never got around to during the year.
  • We asked six experts in reading and writing to share what they plan to read on the beach.

Love and Other Scores by Abra Pressler (and other Australian romantic comedies)

  • The book I’ll be taking to the beach this summer, just in time for the tennis, is one of Pan Macmillan’s latest offerings: Love and Other Scores by Abra Pressler.
  • • Harper Collins published Steph Vizard’s The Love Contract (what if pretending to date your neighbour was the solution to your childcare problems?).
  • • Simon & Schuster published Amy Hutton’s Sit, Stay, Love (the ultimate rom-com for dog people), my own Can I Steal You For A Second?

Three Assassins by Kotaro Isaka

  • With winter receding (David Copperfield, followed by Demon Copperhead), I am looking to what kinds of books might fill my summer, so I’m reading a new-to-me crime/thriller writer, Kotaro Isaka.
  • The novel follows three men who’ve made careers out of hiring themselves as assassins.
  • And best of all, there is a new Kotaro Isaka novel, Mantis, published this month – just in time for the height of summer, under a shady tree by the sea.

War and Peace by Leo Tolstoy and The Flying Doctor’s Christmas Wish by Kathleen Ryder

  • Middlemarch and Moby Dick, and this year will be War and Peace.
  • On a recent trip to central Australia, I met romance fiction author Kathleen Ryder.
  • Her books include Christmas-themed novellas set in Alice Springs, and my pick for this summer is The Flying Doctor’s Christmas Wish.

Skeletons in the Closet by Jean-Patrick Manchette

  • The much-anticipated English translation of the only untranslated novel by the reinventor of dark and darkly witty crime novels, Jean-Patrick Manchette, is the book I most hope to read this summer.
  • Skeletons in the Closet features the hermetic, alcoholic Parisian private eye Eugène Trapon, the only fictional creation of Manchette’s to appear in more than one novel.
  • Trapon is obviously an heir to Dashiell Hammett’s Sam Spade, but Manchette’s novels are only superficially hard-boiled.

Daisy and Woolf by Michelle Cahill and Between You and Me by Joanna Horton

  • Some books can’t be digested at once, so this summer I will be returning to Daisy and Woolf by Goan-Anglo-Indian poet and author, Michelle Cahill.
  • Also on my list is Between You and Me by Brisbane author, Joanna Horton.

The science fiction of Samuel R. Delany and Babel, or the Necessity of Violence by R.F. Kuang

  • This summer, I’m aiming to dive deeper into the works of Samuel R. Delany, who was memorably profiled in the New Yorker earlier this year.
  • Delany is most commonly associated with the New Wave science fiction movement of the 60s and 70s, but his writing spans a fascinating range of genres and subjects.
  • I’ve also wanted to read Babel, or the Necessity of Violence by R.F.
  • Beth Driscoll receives funding from ARC Linkage Project grant LP210300666 Community Publishing in Regional Australia Liz Evans' debut novel will be published by Ultimo Press in 2024.
  • Michelle Cahill is the current Hedberg Writer-in-Residence at the University of Tasmania.

Immuron Clinical Trials Update

Retrieved on: 
Friday, December 22, 2023
Spore, Clostridioides difficile, ASX, Immuron, Principal, Diarrhea, FDA, NMRC, Campylobacter, IMC, Johns Hopkins University, Trial of the century, MD, Agriculture, Clinical trial, GLP, Volunteering, Escherichia, Escherichia coli, CIR, CHIM, Patient, Monash University, Safety, JHU, Clostridioides, Pharmaceutical industry

MELBOURNE, Australia, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to provide shareholders and the market with an update on the company’s clinical development portfolio.

Key Points: 
  • The NMRC has recently completed the in-patient stage of the campylobacter challenge clinical study.
  • Headline results from the clinical trial are anticipated to be reported in H2 2024.
  • The Phase 2 clinical trial is designed to evaluate the safety and protective efficacy of the new product manufactured by Immuron compared to a placebo in a controlled human infection model (CHIM).
  • The inpatient challenge phase of the Travelan clinical study led by Principal Investigator Dr Mohamed Al-Ibrahim at the Pharmaron CPC FDA inspected Clinical Research Facility Inpatient Unit located in Baltimore, Maryland US, has been completed.